Evidence map›Paper›PMID 37833609›Full record

ArticleDoklady. Biochemistry and biophysics2023

Antibodies to Domain I β

T M Reshetnyak, F A Cheldieva, M V Cherkasova, S I Glukhova, A M Lila, E L Nasonov

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

T M ReshetnyakNasonova Research Institute of Rheumatology, Moscow, Russia. t_reshetnyak@yahoo.com.
F A CheldievaNasonova Research Institute of Rheumatology, Moscow, Russia.
M V CherkasovaNasonova Research Institute of Rheumatology, Moscow, Russia.
S I GlukhovaNasonova Research Institute of Rheumatology, Moscow, Russia.
A M LilaNasonova Research Institute of Rheumatology, Moscow, Russia.
E L NasonovNasonova Research Institute of Rheumatology, Moscow, Russia.
Russian Medical Academy of Continuous Professional Education · RUAssociation of Rheumatologists of Russia · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of antiphospholipid antibodies (aPL), which are not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood. The aim of this study was to determine the clinical significance of IgG antibodies for domain 1 of β

Indexed as

Antiphospholipid SyndromeLupus Erythematosus, SystemicThrombosisAntibodies, Anticardiolipinbeta 2-Glycoprotein IFemaleHumansImmunoglobulin GImmunoglobulin MPregnancyAntibodies, Anticardiolipinbeta 2-Glycoprotein IImmunoglobulin GImmunoglobulin Mantibodies to domain I β2 glycoprotein 1antiphospholipid antibodiesantiphospholipid syndromepregnancy morbiditythrombosis

Identifiers

PMID37833609
PMCPMC10739196
OpenAlexW4387606388

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.